Drug Trial Radar · NCT07313891
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 1, 2026
Primary completion
Sep 1, 2029
Study completion Nov 1, 2029
Sponsor
- Lead sponsor
- Relmada Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Conditions
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
- Bladder (Urothelial, Transitional Cell) Cancer
- Urothelial Carcinoma Bladder
- Urologic Cancer
Interventions
NDV-01 (sustained-release gemcitabine-docetaxel)Drug
Intravesical instillation of NDV-01 (sustained-release gemcitabine-docetaxel)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare DFS between study armsTime frame: From date of randomization to at least 2 years of follow-up assessing for DFS events.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.